The nationwide shortage of sodium chloride 0.9 percent intravenous (IV) saline has officially ended, according to the U.S. Food and Drug Administration.

FDA Commissioner Marty Makary, M.D., M.P.H., stated that the shortage has ended due to the combined efforts of the FDA, Administration for Strategic Preparedness and Response, and industry partners. The teams worked together to quickly boost manufacturing and stabilize the supply chain by enabling temporary IV solution imports, expediting manufacturing reviews, and extending product expiry dates.

The sodium chloride 0.9 percent injection shortage is resolved, and it will be removed from the FDA Drug Shortage Database; facilities are advised to use FDA-approved products when available. The FDA is continuing efforts with manufacturers to address other IV fluid shortages and is prioritizing reliable medical product availability.

"The FDA remains focused on doing all we can to help mitigate shortages and prevent them from occurring," Makary said in a statement. "We will continue working diligently to monitor supply levels, anticipate potential disruptions, and support a robust, secure, and transparent supply chain for medical products."